Minor events included 1) recently developed angina or unstable angina, 2) possible or probable MI, 3) TIA, 4) minor stroke, 5) recently developed renal failure, 6) hypertension, and 7) deterioration of vascular disease leading to surgical intervention or angioplasty or local thrombolysis. The occurrence of any of the above minor events did not require treatment discontinuation.
Each end point was defined precisely in the protocol. Each patient contributed only one event; if a patient had both a minor and a major event, only the latter was counted.
Sample Size
From the incidence of major and minor events observed in our country during the PACK study of untreated patients (14% in 18 months), we calculated that to detect a 25% relative reduction of the incidence of major and minor events with the active treatment using the log-rank test,9 the sample would have to be 1, 100 patients in each group (a=0.05 and /8=0.20, one-tailed test). To avoid the risk of a great number of patients being lost to follow-up, the number of patients enrolled was increased by 10%. Statistical Analysis Event-free analysis was performed, establishing survival curves according to the Kaplan-Meier method. The patients lost to follow-up and those who withdrew alive were considered as censored in this analysis. The null hypothesis H0: 6= 1, where 0 is the odds ratio of the two curves, was tested by the log-rank test. The 95% confidence interval was also calculated.10 To perform this analysis, the Proc Lifetest was used (SAS 6.04 ).
Compliance
Compliance with the prescribed medication during the follow-up was verified by counting the remaining capsules at each visit. Patients were considered compliant if they took at least 75% of the prescribed dosage during the entire study.
Results
After the 1-month run-in period, a total of 2,304 patients were randomly allocated to receive either picotamide or placebo. The characteristics of the patients in the two groups were similar at the time of randomization ( Table 1) 
Withdrawal From the Trial
Forty-eight patients on picotamide (4.2%) and 29 (2.5%) on placebo were withdrawn from the study; 18 patients on picotamide and 13 on placebo were withdrawn because of side effects occurring predominantly in the gastrointestinal tract (Table 2) .
Side Effects
Side effects occurred in 14.3% of patients on picotamide and 13.5% on placebo ( Table 3 ). The most com- The intention-to-treat analysis for major and minor events is reported in Table 4 .
The sum of major and minor events was 122 (10.6%) in the picotamide group and 151 (13.1%) in the placebo group (risk reduction, 18.9%;p=0.056 at log-rank test). Five patients in the picotamide group and four in the placebo group died from noncardiovascular complications. Nine patients on picotamide and nine on placebo had more than one minor event.
Patients taking picotamide had 45 major events (3.9%) and 77 minor events (6.7%), whereas patients taking placebo had 52 major (4.5%) and 99 minor events (8.6%) . According to the on-treatment analysis (Table  5 ), the sum of major and minor events was 106 (10.1%) in the picotamide group and 140 (13.1%) in the placebo group (risk reduction, 23%; p=0.029 at log-rank test). Patients taking picotamide had 40 major events (3.8%) and those taking placebo 45 (4.2%); minor events were 66 (6.3%) in the picotamide group and 95 (8.9%) in the placebo group.
The event-free analysis with survival curves is shown in Figure 1 .
Discussion
The objective of the present trial was the evaluation of the clinical efficacy of a new antiplatelet agent in the cardiovascular complications occurring in patients with PVD. Picotamide interferes with the arachidonic acid cascade of platelets by inhibiting TxA2 synthase and antagonizing TxA2 receptors. Unlike aspirin, it does not affect cyclooxygenase. This research was planned according to the clinical suggestions of the largest trial performed in PVD patients, the PACK study,4 which indicated that over a period of 1 year, about 16% of patients may experience major and minor events. The results of our trial are at variance with this finding in that the rate of major and minor events was lower. Even if our trial had foreseen a rate of frequency of events lower than reported in the PACK study, the rate of major events is surprisingly low. In fact, <4% of patients suffered major events over 1 year of follow-up. clinical efficacy of picotamide in a relatively short period of time. By on-treatment analysis, we observed a significant reduction of major and minor events in patients treated with picotamide. In accordance with the PACK study, the event-free analysis indicated that about 1 year of treatment was necessary to observe differences between placebo and picotamide. The small number of major events that occurred in both the treatment and placebo groups did not allow us to observe differences in this category of cardiovascular complications. This should be investigated in a further study, particularly in patients with a greater degree of risk for cardiovascular events than occurred in our study, to evaluate the full potential of such treatment.
The efficacy of antiplatelet treatment in the prevention of cardiovascular complications occurring in PVD patients has been analyzed in two previous large clinical trials.46 Although the PACK study did not show any beneficial effect of ketanserin, the STIMS study showed that ticlopidine prevents cardiovascular complications. By intention-to-treat analysis, the STIMS study showed 11.4% (p=0.24) reduction of vascular complications compared with 18.9% (p=0.056) in our trial; by ontreatment analysis, the STIMS study showed 38.4% (p=0.017) reduction of vascular complications compared with 22.8% (p=0.029) in our trial.
In conclusion, our study further indicates that the clinical history of PVD patients is complicated by cardiovascular events occurring in several circulatory territories.
Picotamide is a well-tolerated drug and seems to protect against global cardiovascular complications occurring in PVD patients; it could be a candidate for future investigations to further assess its clinical efficacy. Appendix Atherosclerotic Disease Evolution by Picotamide (ADEP) Group
